Since only 36.8% of triple negative breast carcinomas showed AR positivity in this study and the overall specificity of AR for breast cancer was low, the use of AR IHC for verifying breast cancer origin of AR positive metastases is limited. This evidence concerns the gene AR and breast carcinoma.